2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 893

Epidemiological Features of Childhood IgA Vasculitis (Henoch-Schönlein) in a French County: A Population-Based Survey
Abstract Number: 894

Late-Onset IgA Vasculitis in Adult Patients Exhibits Distinct Clinical Characteristics and Outcomes
Abstract Number: 895

Relapses and Predictive Factors in Henoch-SchÖnlein Purpura. study of 417 Patients
Abstract Number: 896

Herpes Zoster and the Short Term Risk for Ischemic Stroke in Patients with Autoimmune Diseases
Abstract Number: 897

Intra-Articular Corticosteroids Are Safe and Have No Major Effect on Structural Progression of Synovitic Knee OA: A 2-Year Randomized Controlled Trial of 3-Monthly Triamcinolone Hexacetonide
Abstract Number: 898

A Randomized Double-Blind Study of Denosumab Compared with Zoledronic Acid in Postmenopausal Women with Osteoporosis Previously Treated with Oral Bisphosphonate
Abstract Number: 899

HA20: A Novel Autoinflammatory Disease Caused By Haploinsufficiency of A20, Encoded By TNFAIP3
Abstract Number: 900

A Multidimensional Immunomics Approach Annotates an Immunome Shaped By the Interplay Between the Periphery and the Skin Microenvironment in Systemic Sclerosis
Abstract Number: 901

Novel B Cell-Derived Peptide Regulation of Homeostatic T-Cell Trafficking Is Subverted in Rheumatoid Arthritis
Abstract Number: 902

Inhibitor of DNA Binding 1 As a Fibroblast Derived Inflammatory Angiogenic Agonist in Rheumatoid Arthritis
Abstract Number: 903

CGEN-15001, a Novel B7-like Protein, Controls Inflammation in a Translational Rheumatoid Arthritis (RA) Assay and Induces Treg Driven Long-Term Remission in an Autoimmune Disease Model
Abstract Number: 904

Intracerebroventricular Tweak (TNF-like weak inducer of apoptosis) Induces Depressive-like Behavior and Cognitive Dysfunction in Non-Autoimmune Mice
Abstract Number: 905

Citrullinated Epithelial-Derived Neutrophil-Activating Peptide 78 (ENA-78/CXCL5) Induces Monocyte Migration Via JNK and NFκB Signaling Pathways
Abstract Number: 906

Distinct Expression of IL-36Î±, β, Î³ and Their Antagonists IL-36Ra and IL-38 in Psoriasis, Rheumatoid Arthritis and Crohn’s Disease
Abstract Number: 907

The Natural History of an Inception Cohort of Patients with Inflammatory Polyarthritis Followed for 20 Years: Disease Activity, Disability and Surgery

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].